• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

手机动态码快速登录

手机号快速注册登录

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
194441 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  : i7 @, R; d/ Y4 m* m" Q- ^
, z; [1 L/ a9 P* h
0 t% N1 P3 F8 s9 x( \
Sub-category:
' L; X8 F% S/ zMolecular Targets 0 }% y" o# I  K4 _0 @! C/ S

) m6 s7 Z# _/ o' F, n, @- a, @( \2 M' Y, g& [0 p
Category:
) u, k3 B, K" G5 J9 n$ ~/ BTumor Biology
% U, I( z, x, r  b
. ^6 y- w  ]. K2 n4 @& _  l5 O% R4 P  Z1 o0 \# L" o: Y4 g
Meeting:) G& @, m) a( M6 l. E+ t- v
2011 ASCO Annual Meeting
, L% B, V' v0 F6 p' A$ R
8 o: J. s5 \* e, f$ _$ n8 f/ S+ c# X* l& v8 H
Session Type and Session Title:$ ~3 z& `' Z8 S
Poster Discussion Session, Tumor Biology 7 T, x# J  }7 b1 M( U; Z& I% \% q
+ m+ c5 `1 Q, s; F  _3 x; K
' l+ r' G' s, o- {8 t* c3 V: P
Abstract No:! i7 N! m, q$ s
10517
- M4 z& H( x9 r/ q4 }# t8 U
. ^' P: P0 {  Z- u4 d" t3 ]4 \  ]1 C% X, d' w4 I  O/ U/ H
Citation:! ^+ v& f8 _9 \5 I4 s3 E" L
J Clin Oncol 29: 2011 (suppl; abstr 10517) ! A! C8 D# A9 T, e
* `( ~7 I  a9 q+ {7 y$ T

" k0 m" z6 {# f: F+ [Author(s):
) Z" v' Z5 B" {. m% y, u2 p/ E; {- EJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
3 F5 J. [4 R9 z/ p- G: g3 M- b3 Q; E8 ^3 C
2 C' M$ R5 E* P& N; D5 x; y

' l, z5 o% J, g& H+ L+ E3 s# UAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.8 ^2 H# G( I6 q6 B: \2 ^

3 Y; t) y7 b2 q" |1 i) AAbstract Disclosures
  U8 t( t2 L  c% h. |9 J
( X5 s2 T4 @& |# z# ~# Y; TAbstract:
' B5 @& }# W1 h2 i4 D2 h5 h
( O( k5 Q/ }2 F0 r
4 A3 n9 X$ S1 ~  ~Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
, ^- r9 a3 j0 p9 O, R
/ m: w. Z; i4 m' X" F8 V, U 3 K' B- F2 C0 O9 {) d9 r% x
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 & i1 `( ^3 \: _$ I' h4 @
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
$ I2 K- Z2 j7 o- B8 F6 D
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
, O8 K4 G- N+ [4 s  K易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。( ~5 X4 |9 p. x- {
ALK一个指标医院要900多 ...

9 a! o3 Q. t3 }: h3 K平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?9 g: V6 q& ^4 ]6 {, j. V! M( S
# w6 Y8 S6 W5 X; k4 C: V
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册 手机动态码快速登录

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表